Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic...
26 KB (2,420 words) - 02:40, 26 September 2024
drug cetuximab. They discovered that these individuals had IgE antibodies in their blood that were specifically targeted to the portion of cetuximab which...
36 KB (4,036 words) - 13:05, 12 October 2024
infiltrative disorders such as sarcoidosis. Cetuximab is the first-line therapy for Ménétrier disease. Cetuximab is a monoclonal antibody against epidermal...
10 KB (1,084 words) - 22:07, 15 September 2024
Allergic Facial nerve palsy Anti-cancer treatments such as erlotinib, cetuximab, and panitumumab, which block the function of EGFR (the epidermal growth...
3 KB (220 words) - 20:32, 27 August 2024
Panitumumab (section Panitumumab vs. cetuximab)
the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include...
16 KB (1,421 words) - 15:40, 14 July 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
68 KB (5,999 words) - 20:41, 31 August 2024
the United States in December 2022 for lung cancer and together with Cetuximab in 2024 for colorectal cancer. Adagrasib is indicated for the treatment...
12 KB (751 words) - 20:10, 9 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
92 KB (8,729 words) - 10:30, 16 October 2024
At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration...
17 KB (1,400 words) - 22:21, 10 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
121 KB (13,799 words) - 17:37, 8 October 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
31 KB (3,430 words) - 05:24, 28 August 2024
of a drug depends on the genotype of a patient. For example, Erbitux (cetuximab) increases the survival rate of colorectal cancer patients if they carry...
33 KB (3,391 words) - 18:28, 6 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
149 KB (15,702 words) - 00:28, 14 October 2024
was predictive of a very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer. As of 2008, the most reliable...
45 KB (5,079 words) - 06:39, 25 June 2024
Examples of radiosensitizing drugs include cisplatin, nimorazole, and cetuximab. The impact of radiotherapy varies between different types of cancer and...
113 KB (13,532 words) - 03:03, 25 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
18 KB (1,573 words) - 05:19, 15 October 2024
FOLFIRI is often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the short term...
4 KB (411 words) - 21:05, 6 May 2024
disorders, such as Anorexia nervosa Pregnancy Prostaglandin analogues Cetuximab Bimatoprost, Latanoprost Phenytoin Minoxidil Ciclosporin Topiramate Streptomycin...
4 KB (421 words) - 18:23, 28 March 2024
currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach...
9 KB (1,472 words) - 21:30, 9 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
42 KB (3,935 words) - 04:01, 30 April 2024
Cutsem E, et al. (January 2015). "Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type...
8 KB (767 words) - 09:34, 21 September 2024
receptor inhibitors, of which the three FDA approved ones are aflibercept, cetuximab and panitumumab. The primary difference in the approach to low stage rectal...
145 KB (15,860 words) - 13:57, 30 September 2024
(lomustine) Droxia/Hydrea (hydroxycarbamide) Empliciti (Elotuzumab) Erbitux (cetuximab) Etopophos (etoposide) Ixempra (ixabepilone) Lysodren (mitotane) Megace...
97 KB (7,689 words) - 17:19, 16 October 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
24 KB (1,890 words) - 16:21, 4 October 2024
cetrimide (INN) cetrimonium bromide (INN) cetrorelix (INN) Cetrotide cetuximab (INN) cetylpyridinium chloride (INN) Cevi-Bid cevimeline (INN) cevipabulin...
10 KB (489 words) - 02:02, 1 July 2024
MAbs approved by the FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab...
48 KB (4,964 words) - 23:05, 30 September 2024
therapies used in head and neck cancers include cetuximab, bevacizumab, and erlotinib.[citation needed] Cetuximab is used for treating people with advanced-stage...
105 KB (11,717 words) - 08:58, 9 October 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
24 KB (1,710 words) - 19:18, 30 August 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
14 KB (1,671 words) - 23:17, 4 September 2024
Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab...
34 KB (3,021 words) - 12:39, 5 August 2024